Benchmark Holdings PLC's (LON:BMK) chairman Peter George speaks to Proactive London's Andrew Scott soon after agreeing to sell its vaccine manufacturing assets at its facility in Braintree, UK to Cell and Gene Therapy Catapult. George says he's pleased that Benchmark has been able to be part of the UK solution for vaccine manufacturing.
Benchmark Holdings' Peter George says sale of its vaccine facility is a 'win-win-win'
